07:00 , May 21, 2012 |  BC Week In Review  |  Company News

Casigen Pharma, Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences deal

The institute granted newco Casigen an exclusive, worldwide license to small molecules for diabetes and other metabolic disorders. The preclinical products target estrogen-related receptor alpha (ERR-alpha; ESRRA ; NR3B1 ). Details were not disclosed. Casigen...
00:50 , May 18, 2012 |  BC Extra  |  Company News

Diabetes company Casigen debuts

Newco Casigen Pharma Ltd. (Hong Kong, China) debuted on Thursday with an exclusive, worldwide license to small molecules for diabetes and other metabolic disorders from the Guangzhou Institute of Biomedicine and Health, Chinese Academy of...